CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Budapest, Hungary and 103 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Budapest, Hungary and 234 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Budapest, Hungary and 558 other locations
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-seve...
Phase 2
Budapest, Hungary and 22 other locations
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermati...
Phase 2
Budapest, Hungary and 47 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
Budapest, Hungary and 487 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Budapest, Hungary and 194 other locations
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...
Phase 3
Budapest, Hungary and 246 other locations
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Phase 3
Budapest, Hungary and 342 other locations
Clinical trials
Research sites
Resources
Legal